2. Search Result
Search Result
Results for "

arterial thrombosis

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

11

Natural
Products

7

Isotope-Labeled Compounds

5

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-N0570
    Hydroxytyrosol
    5+ Cited Publications

    DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol

    		 Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Hydroxytyrosol (DOPET; 3,4-Dihydroxyphenethyl alcohol) is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol
  • HY-15468
    IOX2
    Maximum Cited Publications
    18 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    IOX2, a chemical probe, is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM. IOX2 regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 can be used in the study of thrombotic diseases .
    IOX2
  • HY-D0199
    Adenosine 5'-diphosphate disodium
    5+ Cited Publications

    Adenosine diphosphate disodium; ADP disodium

    		 Endogenous Metabolite Cardiovascular Disease
    Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .
    Adenosine 5'-diphosphate disodium
  • HY-124124
    N-Methylnicotinamide
    1 Publications Verification

    		 Endogenous Metabolite Drug Metabolite Cardiovascular Disease Metabolic Disease Cancer
    N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway .
    N-Methylnicotinamide
  • HY-107582
    JW480

    		Ser/Thr Protease Calcium Channel PKC Cancer
    JW480 is a selective KIAA1363/AADACL1 inhibitor with oral activity, featuring IC50 values of 12 nM against human KIAA1363, 20 nM against mouse KIAA1363. JW480 blocks lipid deacetylase activity to restrain HAG metabolism and lowers retinyl ester hydrolase function in hepatic stellate cells. JW480 reduces MAGE lipid levels and inhibits migration, invasion, survival and tumor growth of prostate cancer cells. JW480 lowers PKCδ phosphorylation, facilitates HAGP accumulation, diminishes platelet aggregation, dense granule secretion and Ca 2+ flux, delays arterial thrombosis and prolongs tail bleeding time in rats. JW480 can be used for the study of prostate cancer and thrombosis .
    JW480
  • HY-153999A
    Rondaptivon pegol sodium

    BT200 sodium

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) sodium is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol sodium effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol sodium inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol sodium can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol sodium
  • HY-N1393
    2-Methoxybenzoic acid

    NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether

    		 Carbonic Anhydrase Phospholipase Cardiovascular Disease
    2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
    2-Methoxybenzoic acid
  • HY-N6043
    Hydroxytyrosol acetate

    		Apoptosis Reactive Oxygen Species (ROS) Bacterial SARS-CoV Estrogen Receptor/ERR Infection Neurological Disease Inflammation/Immunology
    Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol acetate
  • HY-108658
    MRS2500 tetraammonium

    		P2Y Receptor Cardiovascular Disease
    MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity .
    MRS2500 tetraammonium
  • HY-P5542
    Vicatertide

    SB-01; Peniel 2000

    		 Factor Xa TGF-beta/Smad Inflammation/Immunology
    Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a Ka of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .
    Vicatertide
  • HY-124124S
    N-Methylnicotinamide-d4

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Derivative Cardiovascular Disease Metabolic Disease Cancer
    N-Methylnicotinamide-d4 is the deuterium labeled N-Methylnicotinamide (HY-124124). N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.
    N-Methylnicotinamide-d4
  • HY-N0570R
    Hydroxytyrosol (Standard)

    DOPET (Standard); 3,4-Dihydroxyphenethyl alcohol (Standard); 3-Hydroxytyrosol (Standard)

    		 Reference Standards Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Hydroxytyrosol (Standard) (DOPET (Standard)) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol (Standard)
  • HY-D0199R
    Adenosine 5'-diphosphate disodium (Standard)

    Adenosine diphosphate disodium (Standard); ADP disodium (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .
    Adenosine 5'-diphosphate disodium (Standard)
  • HY-153999
    Rondaptivon pegol

    BT200

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol
  • HY-10267
    Eribaxaban

    PD-0348292

    		 Factor Xa Cardiovascular Disease
    Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces thrombus formation .
    Eribaxaban
  • HY-N2299
    Morusinol

    		Others Cardiovascular Disease
    Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and  significantly inhibits arterial thrombosis in vivo .
    Morusinol
  • HY-122592
    Zifaxaban

    		Factor Xa Cardiovascular Disease
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .
    Zifaxaban
  • HY-172400
    FXIa-IN-16

    		Factor XI Cardiovascular Disease
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .
    FXIa-IN-16
  • HY-120612
    BMS-884775

    		P2Y Receptor Cardiovascular Disease
    BMS-884775 is a selective and orally active P2Y1 antagonist with an IC50 of 0.1 nM for the human P2Y1 receptor. BMS-884775 has a similar efficacy in preventing arterial thrombosis to Clopidogrel (HY-15283) and Prasugrel (HY-15284), but treatment with BMS-884775 results in shorter bleeding time and lower bleeding risk. BMS-884775 can be used in research related to antiplatelet and arterial thrombosis-associated diseases .
    BMS-884775
  • HY-19219A
    BMS-189664 hydrochloride

    		Thrombin Cardiovascular Disease
    BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research .
    BMS-189664 hydrochloride
  • HY-19219
    BMS-189664

    		Thrombin Cardiovascular Disease
    BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .
    BMS-189664
  • HY-N0570S
    Hydroxytyrosol-d4

    DOPET-d4; 3,4-Dihydroxyphenethyl alcohol-d4; 3-Hydroxytyrosol-d4

    		 Isotope-Labeled Compounds Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Hydroxytyrosol-d4 (DOPET-d4) is the deuterium labeled Hydroxytyrosol (HY-N0570). Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol-d4
  • HY-N0570S1
    Hydroxytyrosol-d5

    DOPET-d5; 3,4-Dihydroxyphenethyl alcohol-d5; 3-Hydroxytyrosol-d5

    		 Isotope-Labeled Compounds Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Hydroxytyrosol-d5 (DOPET-d5) is the deuterium labeled Hydroxytyrosol (HY-N0570). Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol-d5
  • HY-P2021
    BMS 180742

    		Thrombin Cardiovascular Disease
    BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .
    BMS 180742
  • HY-119680
    AT-1459

    		Thrombin Cardiovascular Disease
    AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases .
    AT-1459
  • HY-10281
    YM-60828 methanesulfonate

    		Factor Xa Cardiovascular Disease
    YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
    YM-60828 methanesulfonate
  • HY-11090A
    DPC423

    		Factor Xa Kallikrein Thrombin Ser/Thr Protease Cardiovascular Disease
    DPC423 is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis .
    DPC423
  • HY-11090
    DPC423 free base

    		Factor Xa Kallikrein Thrombin Ser/Thr Protease Cardiovascular Disease
    DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis .
    DPC423 free base
  • HY-10270
    Flovagatran

    TGN 255

    		 Thrombin Cardiovascular Disease
    Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis .
    Flovagatran
  • HY-153998
    BT100 sodium

    		Integrin Cardiovascular Disease
    BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .
    BT100 sodium
  • HY-10271
    Flovagatran sodium

    TGN 255 sodium

    		 Thrombin Cardiovascular Disease
    Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis .
    Flovagatran sodium
  • HY-19229
    TAK-029

    		Integrin Cardiovascular Disease
    TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .
    TAK-029
  • HY-14854A
    Tecarfarin sodium

    ATI-5923 sodium

    		 VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin sodium
  • HY-14854R
    Tecarfarin (Standard)

    ATI-5923 (Standard)

    		 Reference Standards VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin (Standard)
  • HY-117561
    DuP 714

    		Thrombin Cardiovascular Disease
    DuP 714 is an oral active thrombin inhibitor with the IC50 values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi .
    DuP 714
  • HY-N1393R
    2-Methoxybenzoic acid (Standard)

    NSC 3778 (Standard); O-Methylsalicylic acid (Standard); Salicylic acid methyl ether (Standard)

    		 Reference Standards Carbonic Anhydrase Phospholipase Cardiovascular Disease
    2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
    2-Methoxybenzoic acid (Standard)
  • HY-14854S
    Tecarfarin-13C,d3

    ATI-5923-13C,d3

    		 Isotope-Labeled Compounds VKOR Cardiovascular Disease
    Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin-13C,d3
  • HY-N1393S
    2-Methoxybenzoic acid-13C6

    NSC 3778-13C6; O-Methylsalicylic acid-13C6; Salicylic acid methyl ether-13C6

    		 Isotope-Labeled Compounds Carbonic Anhydrase Phospholipase Cardiovascular Disease
    2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- 13C6 is the 13C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
    2-Methoxybenzoic acid-13C6
  • HY-18201
    SCH-602539

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    SCH-602539 is a selective PAR-1 antagonist. SCH-602539 inhibits platelet aggregation in response to PAR-1-selective high-affinity thrombin receptor agonist peptide. SCH-602539 exhibits synergistic antithrombotic effects when used in combination with Cangrelor (HY-19638) .
    SCH-602539
  • HY-19249
    Z-335 sodium

    		Prostaglandin Receptor Metabolic Disease Inflammation/Immunology
    Z-335 sodium is an orally active thromboxane a2 (TXA2) receptor antagonist, with IC50 values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively .
    Z-335 sodium
  • HY-15468A
    IOX2 sodium

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Cancer
    IOX2 sodium is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM. IOX2 sodium regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 sodium can be used in the study of thrombotic diseases .
    IOX2 sodium
  • HY-162164
    Neuroprotective agent 3

    		Others Neurological Disease
    Neuroprotective agent 3 (Compound 21a) is an antioxidant that exhibits neuroprotective effects. Neuroprotective agent 3 significantly increases neuronal viability and induces neuroprotection, as well as improves neurological deficit scores in an in vivo model of transient cerebral ischemia .
    Neuroprotective agent 3
  • HY-124124R
    N-Methylnicotinamide (Standard)

    		Reference Standards Endogenous Metabolite Drug Metabolite Cardiovascular Disease Metabolic Disease Cancer
    N-Methylnicotinamide (Standard) is the analytical standard of N-Methylnicotinamide (HY-124124). This product is intended for research and analytical applications. N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.
    N-Methylnicotinamide (Standard)
  • HY-123400A
    iso-Samixogrel

    iso-DTTX30; iso-DT-TX 30 SE

    		 Prostaglandin Receptor Cardiovascular Disease
    Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
    iso-Samixogrel
  • HY-106111A
    Nafagrel hydrochloride

    		Prostaglandin Receptor Cardiovascular Disease
    Nafagrel hydrochloride is a thromboxane A2 synthetase inhibitor. Nafagrel hydrochloride can prevent the accumulation of thrombus material in a rat model of acute arterial thrombosis .
    Nafagrel hydrochloride
  • HY-N6043R
    Hydroxytyrosol acetate (Standard)

    		Reference Standards Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Hydroxytyrosol acetate (Standard) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
    Hydroxytyrosol acetate (Standard)
  • HY-10279
    YM-60828 hydrochloride

    		Factor Xa Cardiovascular Disease
    YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
    YM-60828 hydrochloride
  • HY-183982
    PAR4 antagonist 9-phosphoric acid

    		Drug Derivative Cardiovascular Disease
    PAR4 antagonist 9-phosphoric acid is a phosphate prodrug of the PAR4 antagonist 9 (HY-183983). PAR4 antagonist 9-phosphoric acid is applicable to research related to arterial thrombosis .
    PAR4 antagonist 9-phosphoric acid
  • HY-183983
    PAR4 antagonist 9

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 9 is an orally active protease-activated receptor 4 (PAR4) antagonist with an IC50 of 2 nM against human targets. PAR4 antagonist 9 functionally modulates PAR4 and inhibits platelet aggregation. PAR4 antagonist 9 can be used in studies related to arterial thrombosis .
    PAR4 antagonist 9
  • HY-164251
    RWJ-671818

    		Thrombin Cardiovascular Disease
    RWJ-671818 is an orally active inhibitor of human α-thrombin with a Ki of 1.3 nM. RWJ-671818 can be studied in research on venous and arterial thrombosis .
    RWJ-671818

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: